These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32222346)

  • 1. Corrigendum to "Traditional Chinese medicine for COVID-19 treatment" [Pharmacol. Res. 155 (2020) 104743].
    Ren JL; Zhang AH; Wang XJ
    Pharmacol Res; 2020 May; 155():104768. PubMed ID: 32222346
    [No Abstract]   [Full Text] [Related]  

  • 2. Corrigendum to "Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19" [Pharmacol. Res. 164 (2021) 105402].
    Di Maria E; Martini P; Gennarelli M
    Pharmacol Res; 2021 Jun; 168():105597. PubMed ID: 33838999
    [No Abstract]   [Full Text] [Related]  

  • 3. Corrigendum to "The role of STAG2 in bladder cancer" [Pharmacol. Res. 131 (2018) 143-149].
    Aquila L; Ohm J; Woloszynska-Read A
    Pharmacol Res; 2019 Apr; 142():315. PubMed ID: 30853313
    [No Abstract]   [Full Text] [Related]  

  • 4. Corrigendum to "Obesity and hypertension" [Pharmacol. Res. 122 (2017) 1-7].
    Seravalle G; Grassi G
    Pharmacol Res; 2017 Oct; 124():156. PubMed ID: 28778374
    [No Abstract]   [Full Text] [Related]  

  • 5. Corrigendum to "Guidelines for preparing color figures for everyone including the colorblind" [Pharmacol. Res. 119 (2017) 240-241].
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():569. PubMed ID: 30279055
    [No Abstract]   [Full Text] [Related]  

  • 6. Corrigendum to "The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors" [Pharmacol. Res. 147 (2019) 104392].
    Bechman K; Yates M; Galloway JB
    Pharmacol Res; 2020 Mar; 153():104634. PubMed ID: 32014340
    [No Abstract]   [Full Text] [Related]  

  • 7. Corrigendum to "Glucocorticoids impair platelet thromboxane biosynthesis in community-acquired pneumonia" [Pharmacol. Res. 131 (2018) 66-74].
    Cangemi R; Carnevale R; Nocella C; Calvieri C; Cammisotto V; Novo M; Castellani V; D'Amico A; Zerbinati C; Stefanini L; Violi F;
    Pharmacol Res; 2018 Sep; 135():268. PubMed ID: 30057000
    [No Abstract]   [Full Text] [Related]  

  • 8. Corrigendum to "The role of the LTB4-BLT1 axis in health and disease" [Pharmacol. Res. 158 (2020) 104857].
    He R; Chen Y; Cai Q
    Pharmacol Res; 2020 Sep; 159():105011. PubMed ID: 32595014
    [No Abstract]   [Full Text] [Related]  

  • 9. Corrigendum to "Inhibition of class I HDACs attenuates renal interstitial fibrosis in a murine model" [Pharmacol. Res. 142 (2019) 192-204].
    Yang M; Chen G; Zhang X; Guo Y; Yu Y; Tian L; Chang S; Chen ZK
    Pharmacol Res; 2019 Aug; 146():104309. PubMed ID: 31270018
    [No Abstract]   [Full Text] [Related]  

  • 10. Corrigendum to "Comparison of two endogenous delivery agents in cancer therapy: Exosomes and ferritin" [Pharmacol. Res. 110 (2016) 1-9].
    Li L; Zhang L; Knez M
    Pharmacol Res; 2017 May; 119():478. PubMed ID: 28159481
    [No Abstract]   [Full Text] [Related]  

  • 11. Corrigendum to "Selective anti-tumor activity of wogonin targeting the Warburg effect through stablizing p53" [Pharmacol. Res. 135 (2018) 49-59].
    Zhao Y; Zhang L; Wu Y; Dai Q; Zhou Y; Li Z; Yang L; Guo Q; Lu N
    Pharmacol Res; 2019 Dec; 150():104498. PubMed ID: 31677863
    [No Abstract]   [Full Text] [Related]  

  • 12. Corrigendum to "Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis" [Pharmacol. Res. 108 (2016) 90-101].
    Tao X; Qi Y; Xu L; Yin L; Han X; Xu Y; Wang C; Sun H; Peng J
    Pharmacol Res; 2020 Jan; 151():104397. PubMed ID: 31780339
    [No Abstract]   [Full Text] [Related]  

  • 13. Corrigendum to "Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention" [Pharmacol. Res. 129 (2018) 216-226].
    Bachurin SO; Gavrilova SI; Samsonova A; Barreto GE; Aliev G
    Pharmacol Res; 2018 Jun; 132():245. PubMed ID: 29555151
    [No Abstract]   [Full Text] [Related]  

  • 14. Corrigendum to "Identification of cromolyn sodium as an anti-fibrotic agent targeting both hepatocytes and hepatic stellate cells" [Pharmacol. Res. 102 (2015) 176-183].
    Choi JS; Kim JK; Yang YJ; Kim Y; Kim P; Park SG; Cho EY; Lee DH; Choi JW
    Pharmacol Res; 2016 Aug; 110():277-278. PubMed ID: 27137797
    [No Abstract]   [Full Text] [Related]  

  • 15. Corrigendum to "Biological characterization of PM226, a chromenoisoxazole, as a selective CB
    Gómez-Cañas M; Morales P; García-Toscano L; Navarrete C; Muñoz E; Jagerovic N; Fernández-Ruiz J; García-Arencibia M; Pazos MR
    Pharmacol Res; 2017 Jun; 120():302. PubMed ID: 28433484
    [No Abstract]   [Full Text] [Related]  

  • 16. Corrigendum to "Nitidine chloride exerts anti-inflammatory action by targeting topoisomerase I and enhancing IL-10 production" [Pharmacol. Res. 148 (2019) 104368].
    Yang N; Yue R; Ma J; Li W; Zhao Z; Li H; Shen Y; Hu Z; Lv C; Xu X; Yang Y; Dai X; Liu X; Yu Y; Zhang W
    Pharmacol Res; 2020 Mar; 153():104624. PubMed ID: 31952896
    [No Abstract]   [Full Text] [Related]  

  • 17. Corrigendum to "Targeting NAD+ degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty" [Pharmacol. Res. 128 (February) (2018) 345-358].
    Ruan Q; Ruan J; Zhang W; Qian F; Yu Z
    Pharmacol Res; 2018 Jun; 132():242-244. PubMed ID: 29610035
    [No Abstract]   [Full Text] [Related]  

  • 18. Corrigendum to "CHST3 and CHST13 polymorphisms as predictors of bosentan-induced liver toxicity in Japanese patients with pulmonary arterial hypertension" [Pharmacol. Res. 135 (2018) 259-264].
    Yorifuji K; Uemura Y; Horibata S; Tsuji G; Suzuki Y; Miyagawa K; Nakayama K; Hirata KI; Kumagai S; Emoto N
    Pharmacol Res; 2019 Jan; 139():570. PubMed ID: 30292639
    [No Abstract]   [Full Text] [Related]  

  • 19. Corrigendum to "MicroRNA-128-3p aggravates doxorubicin-induced liver injury by promoting oxidative stress via targeting Sirtuin-1" [Pharmacol. Res. 146 (2019) 104276].
    Zhao X; Jin Y; Li L; Xu L; Tang Z; Qi Y; Yin L; Peng J
    Pharmacol Res; 2020 Jan; 151():104474. PubMed ID: 31784215
    [No Abstract]   [Full Text] [Related]  

  • 20. Corrigendum to "Protosappanin A protects against experimental autoimmune myocarditis, and induces metabolically reprogrammed tolerogenic DCs" (Pharmacol. Res. 146 (2019) 104269).
    Wu J; Liu M; Mang G; Yu S; Chen Q; Li T; Wang Y; Meng Y; Tang X; Zheng Y; Sun Y; Zhang M; Bo Y
    Pharmacol Res; 2020 Oct; 160():105177. PubMed ID: 32919214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.